Hepatitis C Antibodies
In collaboration with Stanford University, IBT is developing monoclonal antibody (mAb) therapeutics for hepatitis C (HCV). IBT and its collaborators have identified a novel series of neutralizing antibodies against this chronic disease. A unique feature of these antibodies is the ability to prevent the virus from developing resistance. We are currently conducting preclinical studies to characterize and evaluate the candidates.
- Keck et al., Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate, PLoS Pathog, 2012
- Krey et al., Structural basis of HCV neutralization by human monoclonal antibodies resistant to viral neutralization escape, PLoS Pathog, 2013
- Pedersen et al., Neutralization resistance of hepatitis C virus can be overcome by recombinant human monoclonal antibodies, Hepatology, 2013